1. Generics Bulletin
  2. >>Products

Medicines Shortage Risk Builds In Ireland

There Are Currently 180 Medicines In Short Supply In Ireland

 
• By Chloe Kent

Medicines for Ireland has called for action on risks to the country’s medicines supply, with 180 products currently listed as being in shortage.

Ireland surrounded by pills
There are currently 180 medicines in short supply in Ireland • Source: Shutterstock

Industry trade group Medicines for Ireland has highlighted the growing risk to the country’s medicines supply as inflation, energy and transport costs continue to rise while global supply chain disruptions persist. Ireland’s Health Products Regulatory Agency currently lists 180 products as being in shortage, a situation Medicines for Ireland said has potential to “significantly worsen” without intervention.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.